Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 12, 2016, Pages 1685-1696

  Ben Horin, Shomron ^a   Vande Casteele, Niels ^b,c   Schreiber, Stefan ^d   Lakatos, Peter Laszlo ^e  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Biosimilar; CT P13; Extrapolation; Inflammatory Bowel Disease; Infliximab; Infliximab dyyb

Indexed keywords

ABP 501; ADALIMUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CT P 13; INFLIXIMAB; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR;

COMPARATIVE EFFECTIVENESS; COST CONTROL; CROHN DISEASE; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOGENICITY; MACROPHAGE; NONHUMAN; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; INFLAMMATORY BOWEL DISEASES;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES;

EID: 84995572458     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.05.023     Document Type: Review

References (83)

1. 1 European Medicines Agency. Guideline on similar biological medicinal products. October 23, 2014. CHMP/437/04 Rev 1. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed February 28, 2016.
2. 2 U. S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. April 2015. Available at: http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed February 28, 2016.
3. 3 Annese, V., Vecchi, M., Use of biosimilars in inflammatory bowel disease: statements of the Italian Group for Inflammatory Bowel Disease. Dig Liver Dis 46 (2014), 963–968.
4. 4 Devlin, S.M., Bressler, B., Bernstein, C.N., et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol 27 (2013), 567–571.
5. 5 Feagan, B.G., Choquette, D., Ghosh, S., et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 42 (2014), 177–183.
6. 6 Danese, S., Fiorino, G., Michetti, P., Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis 8 (2014), 1548–1550.
7. 7 World Health Organization. Expert Committee on Biological Standardization: guidelines on evaluation of similar biotherapeutic products. 2009. Available at: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed February 28, 2016.
8. 8 Al-Sabbagh, A., Olech, E., McClellan, J.E., et al. Development of biosimilars. Semin Arthritis Rheum 45:Suppl 5 (2016), S11–S18.
9. 9 U. S. Food and Drug Administration. Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm. Accessed April 4, 2016.
10. 10 International Conference on Harmonisation. Q5E Comparability of biotechnological/biological products subject to changes in their manufacturing process. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed April 4, 2016.
11. 11 INFLECTRA prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdf. Accessed April 11, 2016.
12. 12 Park, W., Hrycaj, P., Jeka, S., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72 (2013), 1605–1612.
13. 13 Park, W., Yoo, D.H., Jaworski, J., et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther, 18, 2016, 25.
14. 14 Yoo, D.H., Hrycaj, P., Miranda, P., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72 (2013), 1613–1620.
15. 15 Yoo, D.H., Racewicz, A., Brzezicki, J., et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther, 18, 2016, 82.
16. 16 Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared to maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2016; http://dx.doi.org/10.1136/annrheumdis-2015-208783.
17. 17 Yoo DH, Prodanovic N, Jaworski, J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2016; http://dx.doi.org/10.1136/annrheumdis-2015-208786.
18. 18 Health Canada. Regulatory decision summary for REMSIMA (Control number 184568). August 5, 2016. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds-sdr-remsima-184568-eng.php. Accessed October 7, 2016.
19. 19 Choe, J.Y., Prodanovic, N., Niebrzydowski, J., et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis, 2015 http://dx.doi.org/10.1136/annrheumdis-2015-207764.
20. 20 Kay, J., Wyand, M., Chandrashekara, S., et al. BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses: 54-week results of a randomized, double-blind, active comparator study. Arthritis Rheumatol, 66, 2014 3538 (L20).
21. 21 Nichi-Iko Pharmaceuticals. Phase III testing for NI-071 results (preliminary report). June 22, 2015. Available at: http://www.nichiiko.co.jp/finance/gif/4541_20150622_01.pdf. Accessed February 28, 2016.
22. ®, approved in the European Union. May 30, 2016. Available at: http://media.biogen.com/press-release/biosimilars/flixabi-biogens-infliximab-biosimilar-referencing-remicade-approved-europe. Accessed October 7, 2016.
23. 23 Kaur, P., Chow, V., Zhang, N., et al. A randomized, single-blind, single-dose, three-arm, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP-501 and adalimumab: results of comparison with adalimumab (EU). Ann Rheum Dis, 73, 2014 479 [FRI0264].
24. 24 Amgen press release. Amgen announces positive top-line results from phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with adalimumab in patients with moderate-to-severe plaque psoriasis. October 8, 2014. Available at: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=1975377. Accessed February 28, 2016.
25. 25 Cohen, S.B., Genovese, M.C., Choy, E.H., et al. Randomized, double-blind, phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis. Arthritis Rheum, 67(Suppl 10), 2015, A2054.
26. 26 European Medicines Agency. Remsima assessment report. June 27, 2013. EMA/CHMP/589317/2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Accessed February 28, 2016.
27. 27 Blandizzi, C., Gionchetti, P., Armuzzi, A., et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27 (2014), 1–10.
28. 28 Sedger, L.M., McDermott, M.F., TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants—past, present and future. Cytokine Growth Factor Rev 25 (2014), 453–472.
29. 29 Van den Brande, J.M.H., Koehler, T.C., Zelinkova, Z., et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56 (2007), 509–517.
30. 30 Shen, C., Assche, G.V., Colpaert, S., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21 (2005), 251–258.
31. 31 Van den Brande, J.M., Braat, H., van den Brink, G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003), 1774–1785.
32. 32 European Medicines Agency. Benepali assessment report. November 19, 2015. EMA/CHMP/819219/2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004007/WC500200380.pdf. Accessed April 4, 2016.
33. 33 Born, T., Velayudhan, J., Chen, Y., et al. Demonstration of functional similarity comparing adalimumab to biosimilar candidate ABP 501. Arthritis Rheum, 10(Suppl), 2014 S661 [A1503].
34. 34 U. S. Food and Drug Administration. FDA briefing document. Arthritis Advisory Committee Meeting. BLA 125544. February 9, 2016. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484859.pdf. Accessed February 28, 2016.
35. 35 Vos, A.C., Wildenberg, M.E., Duijvestein, M., et al. Anti–tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 140 (2011), 221–230 e3.
36. 36 Vos, A.C., Wildenberg, M.E., Arijs, I., et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 18 (2012), 401–408.
37. 37 Hebuterne, X., Lemann, M., Bouhnik, Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 62 (2013), 201–208.
38. 38 McRae, B.L., Levin, A.D., Wildenberg, M.E., et al. Fc receptor-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of inflammatory bowel disease. J Crohns Colitis 10 (2016), 69–76.
39. 39 Long, E.O., Kim, H.S., Liu, D., et al. Controlling NK cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31 (2013), 227–258.
40. 40 Louis, E., El Ghoul, Z., Vermeire, S., et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 19 (2004), 511–519.
41. 41 Moroi, R., Endo, K., Kinouchi, Y., et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 65 (2013), 265–271.
42. 42 Louis, E.J., Watier, H.E., Schreiber, S., et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 16 (2006), 911–914.
43. 43 Ternant, D., Berkane, Z., Picon, L., et al. Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn's disease. Clin Pharmacokinet 54 (2015), 551–562.
44. 44 Baumgart, D.C., Lowder, J.N., Targan, S.R., et al. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol 104 (2009), 868–876.
45. 45 Brennan, F.R., Morton, L.D., Spindeldreher, S., et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2 (2010), 233–255.
46. 46 Winkler, U., Jensen, M., Manzke, O., et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94 (1999), 2217–2224.
47. 47 Reinisch, W., Louis, E., Danese, S., The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev Gastroenterol Hepatol 9:Suppl 1 (2015), 17–26.
48. 48 Takeuchi, T., Yamanaka, H., Tanaka, Y., et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol 25 (2015), 817–824.
49. 49 Park, W., Lee, S.J., Yun, J., et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol 11:Suppl 1 (2015), S25–S31.
50. 50 Lambert, J., Wyand, M., Lassen, C., et al. Pharmacokinetic results from a phase 1, single-centre, double-blind, randomised, single-dose, parallel group study comparing 5 mg/kg IV infusion of BOW015 and reference infliximab in healthy male volunteers. Ann Rheum Dis, 74(Suppl 2), 2015 462 (FRI0116).
51. 51 Wynne, C., Petkova, M., Rombout, F., et al. BI 695501, a proposed biosimilar for adalimumab, shows bioequivalence to adalimumab reference products in a randomized, double-blind phase I trial in healthy subjects. Arthritis Rheumatol, 67(Suppl 10), 2015, A2727.
52. 52 Fasanmade, A.A., Adedokun, O.J., Blank, M., et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33 (2011), 946–964.
53. 53 Fasanmade, A.A., Adedokun, O.J., Ford, J., et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65 (2009), 1211–1228.
54. 54 Xu, Z., Seitz, K., Fasanmade, A., et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 48 (2008), 681–695.
55. 55 Brandse, J.F., van den Brink, G.R., Wildenberg, M.E., et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149 (2015), 350–355 e2.
56. 56 Vande Casteele, N., Gils, A., Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol 55:Suppl 3 (2015), S39–S50.
57. 57 Yarur, A.J., Jain, A., Sussman, D.A., et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 65 (2015), 249–255.
58. 58 Lee, H., Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?. AAPS J 16 (2014), 22–26.
59. 59 Ben-Horin, S., Heap, G.A., Ahmad, T., et al. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?. Expert Rev Gastroenterol Hepatol 9:Suppl 1 (2015), 27–34.
60. 60 Feagan, B.G., McDonald, J.W., Panaccione, R., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 146 (2014), 681–688 e1.
61. 61 St Clair, E.W., Wagner, C.L., Fasanmade, A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002), 1451–1459.
62. 62 Ben-Horin, S., Yavzori, M., Benhar, I., et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 65 (2015), 1132–1138.
63. 63 Present, D.H., Rutgeerts, P., Targan, S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999), 1398–1405.
64. 64 Hyder, S.A., Travis, S.P., Jewell, D.P., et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 49 (2006), 1837–1841.
65. 65 Van Assche, G., Lewis, J.D., Lichtenstein, G.R., et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 106 (2011), 1594–1602.
66. 66 Lichtenstein, G.R., Olson, A., Travers, S., et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 101 (2006), 1030–1038.
67. 67 Pallotta, N., Barberani, F., Hassan, N.A., et al. Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol 14 (2008), 1885–1890.
68. 68 Farkas, K., Rutka, M., Balint, A., et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis: experiences from a single center. Expert Opin Biol Ther 15 (2015), 1257–1262.
69. 69 Gecse, K.B., Lovasz, B.D., Farkas, K., et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis 10 (2015), 133–140.
70. 70 Jahnsen, J., Detlie, T.E., Vatn, S., et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 9:Suppl 1 (2015), 45–52.
71. 71 Jung, Y.S., Park, D.I., Kim, Y.H., et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 30 (2015), 1705–1712.
72. 72 Kang, Y.S., Moon, H.H., Lee, S.E., et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 60 (2015), 951–956.
73. 73 Keil, R., Wasserbaeur, M., Zádorvá, Z., et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 51 (2016), 1062–1068.
74. 74 Park, S.H., Kim, Y.H., Lee, J.H., et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 9:Suppl 1 (2015), 35–44.
75. 75 Sieczkowska, J., Jarzebicka, D., Banaszkiewicz, A., et al. Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease: preliminary observations. J Crohns Colitis 10 (2016), 127–132.
76. 76 Murphy, C., Sugrue, K., Mohamad, J., et al. Biosimilar but not the same. J Crohns Colitis, 9(Suppl 1), 2015 S331–S332 (P505).
77. 77 U. S. Food and Drug Administration. Information on biosimilars. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. Accessed March 25, 2016.
78. 78 Vande Casteele, N., Gils, A., Preemptive dose optimization using therapeutic drug monitoring for biologic therapy of Crohn's disease: avoiding failure while lowering costs?. Dig Dis Sci 60 (2015), 2571–2573.
79. 79 ClinicalTrials.gov. Demonstrate noninferiority in efficacy and to assess safety of CT-P13 in patients with active Crohn's disease. Available at: https://clinicaltrials.gov/ct2/show/NCT02096861. Accessed February 28, 2016.
80. 80 ClinicalTrials.gov. The NOR-SWITCH Study. Available at: https://clinicaltrials.gov/ct2/show/NCT02148640. Accessed February 28, 2016.
81. 81 Generics and Biosimilars Initiative. Merck Group starts phase III trial for adalimumab biosimilar. March 18, 2016. Available at: http://www.gabionline.net/Biosimilars/News/Merck-Group-starts-phase-III-trial-for-adalimumab-biosimilar. Accessed April 5, 2016.
82. ® in rheumatoid arthritis patients (ARABESC). Available at: https://clinicaltrials.gov/ct2/show/NCT02260791. Accessed April 5, 2016.
83. 83 ClinicalTrials.gov. Pharmacokinetics and safety study of LBAL in healthy subjects. Available at: https://clinicaltrials.gov/ct2/show/NCT02206867. Accessed April 5, 2016.